2022
Longitudinal analysis of the prevalence and correlates of heavy episodic drinking and self‐reported opioid use among a national cohort of patients with HIV
Oldfield BJ, Li Y, Vickers‐Smith R, Barry DT, Crystal S, Gordon KS, Kerns RD, Williams EC, Marshall BDL, Edelman EJ. Longitudinal analysis of the prevalence and correlates of heavy episodic drinking and self‐reported opioid use among a national cohort of patients with HIV. Alcohol Clinical And Experimental Research 2022, 46: 600-613. PMID: 35257397, PMCID: PMC9018502, DOI: 10.1111/acer.14801.Peer-Reviewed Original ResearchConceptsSelf-reported opioid useOpioid useHeavy episodic drinkingNational cohortRisk factorsDepressive symptomsVeterans Aging Cohort StudyVeterans Health Administration sitesOpioid-related risksHIV disease progressionModifiable risk factorsPast-year cigarette smokingAging Cohort StudyGreater illness severityEpisodic drinkingOpioid-related overdoseHigh-risk drinkingCohort studyProspective cohortIllness severityCigarette smokingClinical correlatesDisease progressionLower oddsMultinomial logistic regressionThe development and initial validation of the Russian version of the BASIS-24
Madden L, Farnum S, Bromberg D, Barry D, Mazhnaya A, Fomenko T, Meteliuk A, Marcus R, Rozanova J, Poklad I, Dvoriak S, Altice F. The development and initial validation of the Russian version of the BASIS-24. Addiction Science & Clinical Practice 2022, 17: 65. PMID: 36435811, PMCID: PMC9701377, DOI: 10.1186/s13722-022-00343-0.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHIV InfectionsHumansOpioid-Related DisordersReproducibility of ResultsRussiaConceptsBASIS-24Addiction treatmentHIV prevention goalsSubset of patientsOpioid use disorderSymptom Identification ScaleMental health statusResultsCronbach’s alpha coefficientsMOUD patientsSeverity InstrumentTuberculosis epidemicEffective treatmentUse disordersHealth statusHealthcare professionalsMental healthPrevention goalsRelationships subscaleTreatment deliveryExploratory principal component analysisOpioidsHIVPatientsAlpha coefficientEECA region
2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidCohort StudiesHIV InfectionsHumansMethadoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisordersSociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV
Oldfield BJ, Li Y, Vickers-Smith R, Becker WC, Barry DT, Crystal S, Gordon KS, Kerns RD, Rentsch CT, Marshall BDL, Edelman EJ. Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV. AIDS Care 2021, 34: 1053-1063. PMID: 34114904, PMCID: PMC8664891, DOI: 10.1080/09540121.2021.1939851.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidChronic PainCohort StudiesGabapentinHIV InfectionsHumansOpioid-Related DisordersProspective StudiesConceptsOpioid useHigh dosesSelf-reported opioid useVeterans Aging Cohort StudyHigh-dose opioidsMean daily doseAging Cohort StudyHigh-dose benzodiazepinesNational prospective cohortOpioid doseOpioid receiptCohort studyFoot painProspective cohortDaily doseIndependent predictorsChronic painPain interferenceClinical variablesClinical correlatesNational cohortMultinomial logistic regressionPWHLogistic regressionOpioidsLong-term Patterns of Self-reported Opioid Use, VACS Index, and Mortality Among People with HIV Engaged in Care
Adams JW, Li Y, Barry DT, Gordon KS, Kerns RD, Oldfield BJ, Rentsch CT, Marshall BDL, Edelman EJ. Long-term Patterns of Self-reported Opioid Use, VACS Index, and Mortality Among People with HIV Engaged in Care. AIDS And Behavior 2021, 25: 2951-2962. PMID: 33569682, PMCID: PMC8442670, DOI: 10.1007/s10461-021-03162-7.Peer-Reviewed Original Research
2020
Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study.
Edelman EJ, Li Y, Barry D, Brennan Braden J, Crystal S, Kerns RD, Gaither JR, Gordon KS, Manhapra A, Merlin JS, Moore BA, Oldfield BJ, Park LS, Rentsch CT, Skanderson M, Williams EC, Justice AC, Tate JP, Becker WC, Marshall BDL. Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 84: 26-36. PMID: 32267658, PMCID: PMC7147724, DOI: 10.1097/qai.0000000000002310.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedOpioid-Related DisordersUnited StatesConceptsOpioid useOpioid use trajectoriesCohort studyPain interferenceSelf-reported opioid useVeterans Aging Cohort StudyVeterans Health Administration sitesInfrequent useOpioid use frequencyMarijuana useAging Cohort StudyNational cohort studyEvidence-based treatmentsGroup-based trajectory modelsProspective cohortBaseline factorsIllness severityMultivariable analysisBenzodiazepine medicationVA carePsychoactive medicationsPrescription painkillersPsychiatric symptomsHeroin useMultinomial logistic regression
2019
Predictors of timely opioid agonist treatment initiation among veterans with and without HIV
Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer KL. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug And Alcohol Dependence 2019, 198: 70-75. PMID: 30878769, PMCID: PMC6836871, DOI: 10.1016/j.drugalcdep.2019.01.038.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyOAT initiationUninfected patientsClinical encountersNational observational cohortAging Cohort StudyAfrican American patientsImproved health outcomesAgonist therapyCohort studyObservational cohortTreatment initiationPredictive factorsEffective treatmentAdjusted modelUninfected controlsUse disordersPsychiatric diagnosisPWHClinical practicePatientsHealth outcomesRural residence
2017
Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine
Madden L, Bojko MJ, Farnum S, Mazhnaya A, Fomenko T, Marcus R, Barry D, Ivanchuk I, Kolomiets V, Filippovych S, Dvoryak S, Altice FL. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine. International Journal Of Drug Policy 2017, 49: 48-53. PMID: 28957756, DOI: 10.1016/j.drugpo.2017.07.025.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNominal group techniqueAgonist therapyBuprenorphine maintenance treatmentAddiction treatment approachesImplementation science strategiesOAT servicesMaintenance treatmentClinical providersTreatment approachesTreatment servicesNGT discussionRegional controlTherapyCliniciansGroup techniqueStructural barriers
2015
Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin DA. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 223-233. PMID: 26009831, PMCID: PMC4446730, DOI: 10.1097/qai.0000000000000591.Peer-Reviewed Original ResearchConceptsLong-term opioidsMorphine equivalent daily doseOpioid receiptRisk of deathLong-term prescriptionUninfected patientsOpioid dosesAntiretroviral therapyHazard ratioDaily dosePropensity scoreHigher opioid dosesCause mortalityHIV statusAvailable patientsMortality riskOpioidsHIVPatientsProspective analysisMortalityBenzodiazepinesDosesDeathRisk
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounseling
2011
Nonmedical use of prescription opioids and pain in veterans with and without HIV
Barry DT, Goulet JL, Kerns RK, Becker WC, Gordon AJ, Justice AC, Fiellin DA. Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain 2011, 152: 1133-1138. PMID: 21354703, PMCID: PMC3086805, DOI: 10.1016/j.pain.2011.01.038.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnalgesics, OpioidChi-Square DistributionCohort StudiesFemaleHealth SurveysHIV InfectionsHumansLogistic ModelsMaleMental DisordersMiddle AgedOdds RatioOpioid-Related DisordersPainPain MeasurementPrescriptionsPsychiatric Status Rating ScalesRetrospective StudiesSelf ReportSurveys and QuestionnairesVeterans HealthYoung AdultConceptsHuman immunodeficiency virusPrescription opioidsComponent summaryHIV statusPain interferenceUse disordersForm Health Survey Mental Component SummarySF-12 Physical Component SummaryVeterans Aging Cohort StudyNonmedical usePharmacy record dataAlcohol Use Disorders Identification Test (AUDIT) scoresAging Cohort StudyPhysical component summaryMental component summaryOpioid use disorderMedian participant ageDrug use disordersLegitimate medical reasonsPast-month cigarette useChi-squared testU.S. military veteransHepatitis COpioid prescriptionsCohort study
2007
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal Of Substance Use And Addiction Treatment 2007, 35: 87-92. PMID: 17933486, PMCID: PMC2587397, DOI: 10.1016/j.jsat.2007.08.004.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentNaloxone treatmentHIV risk behaviorsHIV riskRisk behaviorsHuman immunodeficiency virus (HIV) risk behaviorsDrug-related HIV riskHuman immunodeficiency virus (HIV) riskSex-related HIV risk behaviorsBuprenorphine/naloxoneIntravenous drug useOpioid-dependent personsPrimary care clinicsInconsistent condom useBuprenorphine/Care clinicsMethadone treatmentPrimary careDrug useSteady partnerCondom useBaselineWeeksTreatmentPatientsPharmacological pain control for human immunodeficiency virus–infected adults with a history of drug dependence
Basu S, Bruce RD, Barry DT, Altice FL. Pharmacological pain control for human immunodeficiency virus–infected adults with a history of drug dependence. Journal Of Substance Use And Addiction Treatment 2007, 32: 399-409. PMID: 17481463, PMCID: PMC2128698, DOI: 10.1016/j.jsat.2006.10.005.Peer-Reviewed Original ResearchConceptsSubstance use disordersPharmacological pain controlChronic pain conditionsUse disordersPain controlPain conditionsHuman immunodeficiency virus-infected adultsAberrant drug-taking behaviorsHIV-specific issuesComplaints of painPain management servicesHuman immunodeficiency virusTreatment of painEvidence-based guidanceDrug-taking behaviorClinical reviewImmunodeficiency virusDrug interactionsPatientsDrug dependenceHIVPainDisordersCliniciansPhysicians
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence